Takeda's Edarbi approved as hypertension treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for hypertension, also known as high blood pressure, the agency said Friday.
The FDA approved Takeda’s Edarbi (azilsartan medoxomil).
“High blood pressure is often called the ‘silent killer’ because it usually has no symptoms until it causes damage to the body,” FDA Division of Cardiovascular and Renal Drug Products director Norman Stockbridge said. “High blood pressure remains inadequately controlled in many people diagnosed with the condition, so having a variety of treatment options is important.”